Abstract: This review describes recent research efforts focused on increasing the specificity of contrast agents for proton magnetic resonance imaging (MRI). Contrast agents play an indispensable role in MRI by enhancing the inherent contrast of images; however, the non-specific nature of current clinical contrast agents limits their usefulness. This limitation can be addressed by conjugating contrast agents or contrast-agent-loaded carriers-including polymers, nanoparticles, dendrimers, and liposomes-to molecules that bind to biological sites of interest. An alternative approach to conjugation is synthetically mimicking biological structures with metal complexes that are also contrast agents. In this review, we describe the advantages and limitations of these two targeting strategies with respect to translation from in vitro to in vivo imaging while focusing on advances from the last ten years.
INTRODUCTION
Imaging techniques play a vital role in diagnostic medicine and medical research by aiding with the detection of diseases as well as the monitoring of disease progression and treatment. These imaging modalities include single photon emission computed tomography, positron emission tomography, ultrasound, magnetic resonance imaging (MRI), photoacoustic tomography, and fluorescence imaging, and reviews describing the advantages and limitations of each modality have been published elsewhere [1] [2] [3] [4] [5] [6] . This review focuses on MRI, which is a powerful non-invasive imaging technique that does not use ionizing radiation and has the capability to generate three-dimensional images of deep tissue with good spatial resolution (25-100 m) [6] .
Conventional MRI images are produced by mapping either the relaxation rates or densities of the nuclear spins of water protons in a magnetic field. Differences in relaxation rates are due in part to the chemical composition of the surrounding environment; however, the inherent levels of signal intensity that result from the differences in relaxation rates of water protons are often not sufficient to produce satisfactory contrast. Therefore, chemicals known as contrast agents are used in MRI to catalytically accelerate the relaxation rate of water protons to obtain contrast-enhanced images. Paramagnets including Gd III , Mn II , and Mn III are referred to as "T 1 agents" because of their influence on longitudinal (T 1 ) relaxation rates, and superparamagnetic iron oxide (SPIO) particles are referred to as "T 2 agents" because of their influence on transverse (T 2 ) relaxation rates [7] . The ability of a contrast agent to influence contrast is measured in terms of relaxivity, and relaxivity changes in response to changes in *Address correspondence to this author at the Department of Chemistry, Wayne State University, Detroit, MI 48202, USA; Tel: 313-577-2070; Fax: 313-577-8822; E-mail: mallen@chem.wayne.edu physical parameters including magnetic field strength, temperature, and solvent composition. This dependence of relaxivity on measurement conditions often prevents a meaningful direct comparison of agents in different studies. Hence, in this review, we list the physical parameters reported for each example to avoid misinterpretation that could arise due to direct comparison of agents measured under different conditions ( Table 1) .
In current clinical MRI (1.5-3 T), Gd III -based complexes are the most commonly used contrast agents, and these agents are non-specific; they do not accumulate in particular tissues or organs of interest. Non-specific contrast agents are useful in the imaging of pathologies like tumors, lesions, and inflammation because these agents aid in the differentiation of healthy and diseased tissues based on vascular volume, vascular perfusion, and vascular permeability [8] . While these non-specific contrast agents are used in ~35% of clinical scans [9] , their utility in the early detection of disease and imaging of specific biological regions is limited. This limitation arises because diseases often do not display changes in vasculature, and if observable changes in vasculature occur, they are likely to occur in later stages of diseases. One method to address the limitation of non-specificity is the use of targeted contrast agents. Since the first descriptions of targeted contrast agents [10, 11] , this topic has become a focus in the field of MRI and contrast agent research because of the potential to enable molecular imaging in addition to anatomical imaging. The importance of targeted contrast agents has been described in several recent reviews [8, 3, [12] [13] [14] [15] [16] [17] [18] . These reviews discuss the development and properties of T 1 and T 2 agents and the use of different biomarkers as targets. In this review, we describe targeted contrast agents for proton MRI that were developed during the last ten years using two different synthetic strategies with a focus on agents that have been tested both in vitro and in vivo to emphasize limitations that must be overcome to enable the clinical use of targeted contrast agents.
The design of target-specific contrast agents involves two types of strategies: the most common strategy is to conjugate a contrast agent with an antibody, peptide, or a small organic molecule that enables interactions with a target. A second strategy is to transform a contrast agent directly into the targeting moiety by mimicking the structure of a molecule that naturally interacts with a desired target. The development of targeted contrast agents with these two strategies has led to successful targeting in vitro, and some agents have been successfully translated to enable in vivo visualization of targets. The remainder of this review is organized into these two strategies: conjugation and mimicking.
THE CONJUGATION STRATEGY
Direct conjugation of derivatives of clinically approved contrast agents to peptides, antibodies, or small organic molecules is a popular and relatively simple method of achieving target specificity. All directly conjugated contrast agents contain three parts: a targeting moiety, a contrastenhancing unit, and a linker that connects the other two parts (Fig. 1) . When linking the contrast-enhancing unit and targeting moiety, either metalate-then-conjugate or conjugatethen-metalate methods can be used [19] , and conjugation generally results in the formation of biologically stable amides, ethers, thioesters, or triazoles. Low molecular weight ( 30 kDa) targeted contrast agents are desirable because their small size enables diffusion to small areas and facile clearance, but this type of targeted contrast agent faces the challenge of low sensitivity: with small Gd III -based contrast agents, micromolar or greater concentrations are needed to achieve satisfactory contrast in vivo [20, 21] . Therefore, contrast agents that possess both high relaxivity and long circulation times are desirable to lower the dose of contrast agent. To increase sensitivity, targeting moieties and Gd IIIcontaining complexes are conjugated to macromolecules including dendrimers, polymers, proteins, liposomes, and nanoparticles. These agents obtain high relaxivity by slowing the molecular tumbling rate, by combining several contrastenhancing units per targeting moiety, or both. In the following section, we describe the use of the conjugation strategy to synthesize targeted imaging agents using both a single contrast-enhancing unit (monomeric) and multiple contrastenhancing units (multimeric), and we describe the selectivity and sensitivity of the resulting agents in vitro and in vivo. 
Monomeric Target-specific Contrast Agents
Monomeric targeted contrast agents contain one contrastenhancing unit per targeting moiety; therefore, to achieve satisfactory contrast enhancement with these agents, targets with high expression levels need to be selected. Examples of such highly expressed targets include biomarkers associated with tumors; consequently, many monomeric tumor-targeted contrast agents are reported. Conjugation of steroids with contrast agents enables targeting of receptors on tumor cells because hormone receptors are over-expressed by various tumors. 21-Hydroxyprogesterone and 17 -estradiol are steroids that interact with progesterone receptors and estrogen receptors that are over-expressed by uterine, breast, ovarian, and prostate carcinomas. These two steroids were conjugated with Gd III -containing complexes to produce monomeric contrast agents 1 and 2, respectively (Fig. 2) [22, 23] . The relaxivity of 1 is 5.35 mM -1 s -1 (1.41 T, 37 °C, and 1% dimethylsulfoxide in water), and the relaxivity of 2 is 6.8 mM -1 s -1 (9.4 T and phosphate buffered saline (PBS)). Because these relaxivity values are similar to those of clinically used nonspecific agents [20, 24] , doses similar to those used for nonspecific agents are needed to enable good contrast (0.15 mmol/kg for 1 and 0.075 mmol/kg for 2). In vivo imaging of xenograft mice using intraperitoneal or subcutaneous injections of 1 at 7.05 T resulted in contrast enhancement of progesterone-receptor-positive tumors with respect to progesterone-receptor-negative tumors (Fig. 3) . Furthermore, agent 1 labels tissues that express progesterone receptors including the uterus and ovaries [22] . Imaging of xenograft mice using 2 (tail-vein injection at 9.4 T) demonstrated the targeting efficiency of this agent toward estrogen-receptor-positive tumors by enhancing contrast relative to estrogen-receptornegative tumors [23] . The success of these two agents in enhancing contrast in tumors relies on the over expression of receptors in tumors relative to normal tissues.
Integrins are other receptors targeted for imaging. Integrin-targeted contrast agents have the potential to enable the detection of angiogenesis and thrombosis. The cyclic peptide cRGD is a widely used targeting moiety for integrins [25] [26] [27] . An IIb 3 integrin-receptor-targeted agent reported by Fayad and co-workers to detect thrombosis demonstrates the importance of high receptor concentration to obtain good contrast enhancement with monomeric agents [25] . Their contrast agent, 3, consists of cRGD conjugated to Gd III 1,4,7,10-tetraazacyclododecane-N, N´, N´´, N´´´-tetraacetic acid (DOTA). This agent has a relaxivity of 9 mM -1 s -1 (1.41 T and 40 °C) and binds with the IIb 3 receptor as well as the V 3 receptor. In vivo studies with mouse models of thrombosis demonstrated the ability of 3 to increase contrast of activated platelets with a 0.1 mmol/kg dose injected in the tail-vein. The reason for the success of 3 as a thrombosistargeted contrast agent is the high expression of the IIb 3 receptor (40,000 per platelet) in platelets relative to V 3 (~1,500 per platelet) [28] . When the expression level of a target is low, larger amounts of monomeric agents are needed to achieve contrast enhancement. For example, cRGD-conjugated contrast agent 4 ( Fig. 2) was studied as a means to selectively image the V 3 integrin receptor that is over-expressed in hepatocelluler carcinomas [27] . The relaxivity of contrast agent 4 is 7.4 mM -1 s -1 (1.5 T and 25 °C), and in vivo imaging of H-ras12V transgenic mice bearing hepatocellular carcinomas at 1.5 T (tail-vein injection of 1.43 mmol/kg of 4) enhanced contrast of the tumor region. Tumor cells used in this study have a low concentration of V 3 receptors, and the contrast agent has a moderate specificity for these receptors; thus, the high dose used in this study was needed to saturate the receptors. The integrin-receptor-targeted examples 3 and 4 demonstrate the importance of biomarker expression level for targeted imaging. However, in vitro success is often difficult to translate in vivo even with biomarkers expressed at high levels and high-affinity targeting moieties. For example, the estrogen-receptor-targeted contrast agent 5 ( Fig. 2) reported by Degani and co-workers has a relaxivity of 4.7 mM -1 s -1 (9.4 T and PBS). However, agent 5 (using same dose as 2) was not able to produce significant enhancement in vivo despite a higher in vitro binding affinity with a binding inhibition constant, K i , of 0.13 mol/L for estrogen receptors than 2 (K i = 0.97 mol/L) [23] . This discrepancy likely was due to the accumulation of 5 in muscle tissues causing a reduction in the effective dose for estrogen-receptor-positive tumors.
Further highlights of the inconsistencies that are often observed between in vitro and in vivo systems are exemplified by two studies that target the folate receptor, which is found in high concentrations in tumors. Folate-conjugated monomeric contrast agent 6 ( Fig. 2) has a low relaxivity of 1.28 mM -1 s -1 (4.7 T and aqueous solution) [29] . In vitro studies of 6 with human folate-receptor-positive ovarian carcinoma (IGROV-1) cell lines did not produce signal enhancement; however, inductively coupled plasma-mass spectrometry results with competitive binding experiments confirmed the uptake of 6 by the cells. Despite the negative imaging results of the in vitro studies, in vivo studies at the same field strength demonstrated increased contrast of tumors in xenograft mouse models using a micromolar dose of 6 delivered intravenously. Conversely, the folate-related agent 7 reported by Wang and co-workers containing a dimeric Gd III chelate conjugated to folate has a high relaxivity of 21 mM -1 s -1 per Gd III ion (1.41 T, 37 °C, and water) [30] . In vitro studies with IGROV-1 cells confirmed the uptake of 7 through folate receptors. While contrast agent 7 was unable to enhance contrast in tumors implanted in rat models in vivo at 2 T (0.03 mmol/kg dose), the relaxation rate in the tumor increased and R 1 (the difference between the T 1 relaxation rates before and 1 h after contrast enhancement) was 0.214 s -1 for 7 relative to non-targeted agents (0.112 s -1 ), suggesting that the agent was retained in the tumor. Hence, the poor enhancement obtained in this study likely is not related to the selectivity of the contrast agent.
Conjugating a high relaxivity agent to a targeting moiety often is advantageous because it leads to an increase in contrast with lower doses of agent. Recently, Yang and coworkers reported contrast agent 8 targeted to human epidermal growth factor receptor type 2 (HER2) (Fig. 2) using a designed protein chelator for Gd III , and agent 8 has a high relaxivity (21 mM -1 s -1 , 1.41 T, 37 °C, and tris(hydroxymethyl) aminomethane (Tris) buffer at pH 7) [31] . The contrast agent is conjugated to a HER2 affibody as the targeting moiety, a fluorescent dye to enable tracking by fluorescence microscopy, and polyethylene glycol moieties to achieve biocompatibility. Agent 8 demonstrated increased in vivo enhancement of tumors in xenograft mice using a tail vein injection of 100 fold lower dose (0.24 mol per mouse) than is used commonly with clinical contrast agents for routine MR imaging experiments.
Although, a protein was used as the chelating moiety in the previous example, more often proteins are used as targets. There are several contrast agents that label human serum albumin, including Gd III 3,6,10,16-tetraazabicyclo [10.3.1]hexadecane-3,6,10-tris(methanephosphonates) 9, MS-325 10, and Gd III DOTA-deoxycholic acid 11 ( Fig. 2 ) [26, 32, 33] . These agents bind to albumin leading to increased circulation times; consequently, they are used as blood pool imaging agents. Fibrin and collagen are other well explored proteins for targeted imaging because they are found in high concentrations in angiogenesis, thrombosis, atherosclerosis, and other wound-healing processes. The cyclic decapeptide cCGLIIQKNEC (CLT1) conjugated to Gd III diethylenetriaminepentaacetic acid (DTPA), 12, (Fig. 2 ) is a fibrin-fibronectin-labeling agent with a relaxivity of 4.22 mM -1 s -1 (3 T and room temperature) [34] . In vivo tumor imaging of human colon cancer xenografts in mice showed enhancement of tumors using a 0.1 mmol/kg dose because of the high concentration of fibrin-fibronectin associated with the neovascularization of tumors.
Imaging diseases in brain is more challenging than other parts of the body because of the tight regulation in transportation of compounds across the blood brain barrier (BBB). Some diseases like brain tumors disrupt the BBB allowing contrast agents to accumulate in the interstitial spaces that outline the tumor region. However, many other abundant neuropathologies including Alzheimer's disease and multiple sclerosis do not disrupt the BBB during early stages of the diseases. Hence, the synthesis of targeting biomarkers to image neuropathology with MRI is an active area of research because of the current lack of in vivo detection methods. -Amyloid peptides and myelin are two components that have been investigated as targets [35] [36] [37] [38] [39] .
-Amyloid plaques are potential biomarkers for imaging Alzheimer's disease [35] [36] [37] . A derivative of amyloid peptide conjugated with Gd III -containing complexes, 13, was found to label amyloid plaques in vivo [35] . MRI imaging at 7 T of brains removed from transgenic mice (APP-PS1) that were injected intravenously with 13 demonstrated contrast enhancement of plaques. This result implies that 13 has the ability to cross the BBB. However, in vivo imaging was not reported; hence, the applicability of 13 for in vivo imaging cannot be predicted without further research.
Myelin is another biomarker for various neurodegenerative diseases including multiple sclerosis. Wang and coworkers reported myelin-targeted contrast agent 14 ( Fig. 2 ) [38, 39] . Contrast agent 14 contains a coumarine derivative as the targeting unit conjugated to Gd III DOTA, and this agent has a relaxivity of 5.2 mM -1 s -1 (9.4 T, 21 °C, and water). Ex vivo T 1 mapping of mouse brains incubated with 14 demonstrated the specificity of 14 for myelin [38] . Subsequent in vivo studies were carried out with intracerebroventricular infusions (~1 mg (1.14 Gmol)/kg) because of the poor BBB penetration of 14. These studies demonstrated the specificity for myelin and the ability of 14 to highlight demyelination with T 1 mapping at 9.4 T [39] . However, conventional MR imaging was not reported with this agent, which likely was due to low sensitivity that needs to be improved for clinical translations of 14.
While monomeric agents are desirable because of their low molecular weight, in general, studies of monomeric targeted agents reveal the need for biomarkers with high local concentrations or for the use of large doses of contrast agents to achieve enhancement of targets due to the low sensitivity of these agents. Therefore, it is essential to increase the sensitivity of target-specific agents to image biomarkers with relatively low expression levels.
Multimeric Target-specific Contrast Agents
Compared to monomeric agents, multimeric contrast agents can be used to image biomarkers that have relatively low expression levels. Also, the blood circulation of multimeric contrast agents tends to be longer than that of monomeric agents because the large size of multimeric agents prevents rapid clearance via the kidneys; hence, multimeric agents often have a longer time to interact with targets. Furthermore, high molecular weights result in slow tumbling rates that increase relaxivity, and multimeric targeted contrast agents contain up to thousands of contrast-enhancing units and targeting moieties that also increase relaxivity. The long circulation times and high relaxivities of multimeric agents enable the use of smaller doses than monomeric agents for in vivo imaging.
Fibrin-targeted agent 15 (Fig. 4) [40] . The effectiveness of 15 as a targeted contrast agent in vivo was demonstrated by imaging pulmonary emboli and cerebral venous sinus thrombosis [41, 42] . Both studies were performed using swine models containing engineered human blood clots, and contrast enhancement was reported at 1.5 T after intravenous injection of 4 mol/kg of 15. These studies reveal the specificity of 15 for fibrin and the applicability of 15 to the detection of fibrin-associated diseases in vivo with low doses.
A structurally similar agent to 15 is collagen-targeted contrast agent 16 (Fig. 4) To increase relaxivity by increasing Gd III -loading, macromolecules including polymers, dendrimers, nanoparticles, and liposomes are used [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] . These macromolecules act as carriers to transport large numbers of contrast agents and targeting moieties. The expectation with this method is that contrast enhancement will be observed even if only a small number of target molecules are labeled. Conjugation of several Gd III -containing complexes and targeting moieties to poly(L-glutamic acid)cystamine or N-(2-hydroxypropyl) methacrylamide produced contrast agents 17 and 18 (Fig. 4) for targeting integrins [45, 46] Dendrimers are also used as carriers for multimeric agents. Polyamidoamine (PAMAM) dendrimers are widely used as a macromolecular delivery system because they can be functionalized easily and are biocompatible [48] [49] [50] . In vivo imaging using agents 20 and 21 composed of folic acid and Gd III -containing chelates conjugated to PAMAM dendrimers enabled contrast enhancement of human epidermoid carcinomas in xenograft mice [49, 50] . The relaxivity of these contrast agents is higher than monomeric agents, for example 64 [54, 56, 57] . Lanza and co-workers reported integrin-targeted contrast agents for tumor imaging using Gd III -containing nanoparticles [54, 55] . These nanoparticles, 22, containing an V 3 integrin antagonist and Gd III DTPA, were used to visualize early tumor angiogenesis in xenograft mice using intravenous injections of 0.5 mL/kg (~0.03 nmol particles/kg or 2.7 mol Gd III /kg based on data in [54] ). Each nanoparticle contained ~90,000 Gd III ions with a relaxivity of 1,800,000 mM -1 s -1 per particle (~20 mM -1 s -1 per Gd III ion, 0.47 T, and 40 °C). Nanoparticle 22 produced a 173% contrast enhancement in melanoma xenografts at 1.5 T [54] . Lu and co-workers recently reported a nanoglobular system 23 (Fig. 4) containing the decapeptide CLT1 and Gd III DOTA to target fibrin-fibronectin [56] . The generation 3 nanoglobular system with a molecular relaxivity of 353 mM -1 s (Fig. 5) . The nanoparticles were excreted via the renal pathway, which is important for the translation of these contrast agents into clinical applications.
Although, nanoparticles are potential carriers to increase the local concentration of contrast agent at sites of interest, maintaining a size smaller than the renal excretion threshold (~8 nm) and a high relaxivity is needed to enable the clinical application of these agents. To achieve high relaxivity with nanoparticles, attachment of Gd III -containing chelates to the surface of nanoparticles is more desirable than encapsulation [57] because encapsulation decreases relaxivity of nanoparticles. For example, Gd III DOTA encapsulated in chitosan nanoparticles 24 (Fig. 4) [58, 59] . These low relaxivities resulted from the reduced accessibility of water molecules to the Gd III ions due to the encapsulation inside of the hydrophobic nanosystems. Attaching Gd III -containing chelates on particle surfaces enables facile access of water molecules to Gd III ions; however, attaching a large number of Gd III -containing chelates on the nanoparticle surface increases the risk of leaching Gd III ions.
Because of the toxicity of unchelated Gd III ions, several research groups have studied Mn II -containing nanosystems for targeted imaging [60, 61] . Although, Mn II (spin 5/2) has a lower relaxivity than Gd III (spin 7/2), nanosystems with large Mn II loadings can produce contrast enhancement of targets. Lu and co-workers reported a nanoglobular system 26 (Fig.  4) 
Superparamagnetic Target-specific Contrast Agents Using the Conjugation Strategy
Superparamagnetic iron oxide (SPIO) nanoparticles coated with polymers are another class of contrast agents for MRI. These agents enhance the contrast of images by decreasing signal intensity in T 2 -and T 2 * -weighted imaging and, consequently, darkening the target area relative to surrounding tissues. Although, the darkening effect (negative contrast) is not ideal for anatomical imaging, many SPIObased target-specific contrast agents are reported with T 2 -weighted imaging because they can be used for target detection in post-injection images when compared to pre-injection images. Additionally, SPIO-based agents can be converted to positive imaging agents using different pulse sequences and post-processing positive-contrast techniques [62] . Although, these new positive imaging techniques with SPIO nanoparticles have been reported with cell labeling and tracking studies, we have limited our discussion on SPIO-based targetspecific contrast agents in this section to conventional T 2 -or T 2 * -weighted imaging.
SPIO nanoparticles are used in MRI because of the biocompatibility of iron oxide nanoparticles and high T 2 relaxivity for contrast enhancement. These biocompatible SPIO nanoparticles are taken up by the reticuloendothelial system (RES) in cells; hence, in early studies, SPIO nanoparticles were used to detect lesions in RES-rich organs including the liver, spleen, and lymph nodes without the use of a conjugated targeting moiety [17] . However, recent research has focused on conjugating targeting moieties to the nanoparticle surface to achieve selectivity to areas other than hepatic lesions. Conjugation of targeting moieties to the iron oxide core is possible because of the polymeric coatings used to stabilize the SPIO nanoparticles. Rajabi and Tsourkas and co-workers reported the use of targeted SPIO nanoparticles for selective detection of tumors in vivo [63, 64] . The contrast agents reported by these groups target the HER2 receptor in tumor tissues and consisted of magnetic nanoparticles modified with the monoclonal antibody Trastuzumab, 29, or with a HER2-affibody, 30 (Fig. 4) . To synthesize particle 29, the targeting antibody was conjugated to the nanoparticle using an amine-containing linker incorporated into a dextran coating [63] . Whereas, in particle 30, the azide-alkyne Huisgen cycloaddition (often referred to as "click" chemistry) was used to conjugate an alkynated linker containing the HER2-targeted affibody to a polymer coating functionalized with azides [64] . Agent 29 enhanced the tumor regions in mouse models relative to surrounding tissues with 30 mol/kg (tail-vein injections). For agent 30, a 10 mg (0.18 mmol) Fe/kg dose was used (retro-orbital injection) to enhance contrast of tumors (Fig. 6) . Iron oxide nanoparticles conjugated with urokinase-type plasminogen activator (uPA) peptide, 31, used carboxylates on the polymer coating to conjugate with targeting moieties [65] . The uPA peptide was engineered to contain an amine that enables conjugation with nanoparticles via amide linkages. Contrast agent 31 has relaxivity (T 2 ) value of 124 mM -1 s -1 (3 T) and targets uPA receptors that are over-expressed in tumors. In vivo imaging with intravenous injections of 31 at 3 T using mammary carcinoma bearing mouse models demonstrated enhanced contrast in the tumor region, but contrast enhancement within the tumor was heterogeneous. This heterogeneous distribution of 31 in tumor tissue and the resultant decrease in signal intensity enabled an understanding of receptor distribution in addition to tumor detection. Another cancer-cell-targeted SPIO-nanopartcle-based contrast agent, 32 (Fig. 4) , acts as a drug delivery vehicle as well as an imaging probe [66] . In this study, SPIO nanoparticles were labeled with a monoclonal antibody, a fluorescent probe, and four anticancer drugs that release from the SPIO nanoparticle in response to changes in pH. Although, in vivo imaging was not performed, in vitro studies of this potential theranostic agent using human colon cancer cells (LS174T) demonstrated a reduction of T 2 in cells incubated (0.03 mg/mL and 37 °C) with 32 (55.5 ms) with respect to untreated control cells (117.3 ms) at 7 T. Other than tumor imaging, SPIO nanoparticles are reported to detect renal inflammations. Thurman and coworkers reported the use of SPIO nanoparticles, 33, conjugated with a recombinant protein that targets the complement receptor type 2 in kidneys for in vivo studies of glomerulonephritis. A dose of 10-16 mg of particles/kg enhanced contrast of the kidneys of diseased mice and demonstrated the potential for selective visualization of renal inflammation without the need for invasive renal biopsies [67, 68] .
The direct conjugation of targeting moieties with contrast agents or carrier molecules containing contrast agents is synthetically a simple approach to achieve selectivity. Therefore, both in vitro and in vivo imaging are reported for many targeted agents synthesized with this strategy. Monomeric targeted agents interact with or are internalized by targeted cells and can clear from the body easily because of their small size. But, monomeric agents often have low sensitivity. Multimeric agents that bear up to thousands of contrastenhancing units and targeting moieties have high relaxivities because of their large size and the number of conjugated contrast agents. However, large size can result in difficulties in clearance. Therefore, while each class of targeted agents has potential niche uses, multimeric agents of intermediate size that have high relaxivities but remain within the renalclearance threshold likely will be the agents with more potential for in vivo applications in the future.
TARGET-SPECIFIC CONTRAST AGENTS DE-SIGNED WITH THE STRUCTURE-MIMICKING STRATEGY
Transforming contrast agents into structural mimics of molecules that interact with specific tissues and receptor molecules is a targeting strategy that converts contrast agents directly into targeting moieties. However, the synthesis of contrast agents that mimic the structure of biologically active molecules can be synthetically challenging. Several attempts to synthesize targeted biomimetic contrast agents have been reported and include porphyrin-, high-density-lipoprotein-, and ferritin-based agents [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] .
Porphyrins selectively accumulate in necrotic tissues and interact with neurons [69, 80, 81] ; porphyrins also form stable complexes with some metal ions and possess optical properties that are advantageous for imaging studies. Consequently, several porphyrin-based contrast agents are reported for tumor targeting. Mn III -containing porphyrin-dextran system 34 (Fig. 7) was used to visualize tumors in vivo. Porphyrin agent 34 has a relaxivity of 8.90 mM -1 s -1 (4.7 T and aqueous solution) and enhances tumor contrast in mice bearing hepatoma tumors using a 0.05 mmol Mn III /kg dose (intravenous injection) [70] . Another Mn III -based porphyrin, 35 ( Fig. 7) , was reported as a brain-tissue-specific contrast agent that is cell permeable and labels neuronal cell bodies in the hippocampus [71] . However, the introduction of contrast agent 35 to rat brains (0.017-0.02 mol/kg dose) using direct injection and the long retention time reported in brain tissues (t 1/2 10 days) suggest areas for future research with this contrast agent.
Although, Mn
III -containing porphyrins have higher relaxivities than clinical contrast agents, they have lower relaxivities than Gd III -containing porphyrins [70, 72] . Two Gd IIIcontaining porphyrins 36 and 37 ( Fig. 7) were reported for in vivo melanoma imaging (relaxivities of 16.3 and 31.7 mM -1 s -1 at 7 T, 23 °C, and aqueous solutions for 36 and 37 respectively) [72, 73] . In vivo imaging of xenograft nude mice using 0.1 mmol/kg of 36 and 37 (intravenous bolus injections) showed contrast enhancement in tumors due to specific accumulation [72] . However, Gd III -containing porphyrins are kinetically unstable in solution because of the size disparity between the metal ion and porphyrin cavity [74, 82] . Hence, expanded porphyrin systems, such as texaphyrins, are used to form stable complexes with Gd III . Like porphyrins, Gd III -containing texaphyrins accumulate in tumors and enhance contrast [83] . The relaxivity of Gd III -containing texaphyrin 38 (Fig. 7) is 18 mM -1 s -1 (1.2 T, 25 °C, and aqueous saline) [84] . Because of the specific accumulation of texaphyrins in tumors and the optical properties of these molecules, texaphyrins are used as radiation sensitizers for tumor therapy and as tumor-specific imaging probes [85] .
Another porphyrin structural mimic used as a targeted contrast agent is the copper phthalocyanine dye Luxol fast blue MBS (LFB MBS) 39 (Fig. 7) . Complex 39 is a histology stain for myelinated neurons that was studied as a contrast agent for MRI in ex vivo brain tissues [81] . The relaxivity of this agent is low (0.15 mM -1 s -1 , 4.7 T, and ethanol) partially because the Cu II ion has a spin of 3/2. Heavily myelinated regions appeared brighter in images when stained with LFB MBS with respect to control experiments, but to attain good contrast enhancement, similar molecules containing metals with higher spin values need to be synthesized.
Synthetic high-density lipoprotein (HDL) nanoparticles are another class of targeted contrast agents that mimic natural molecular entities to achieve selectivity. HDL particles are made into contrast agents by incorporating chelated Gd III into the outer phospholipid coating or by loading the core of the HDL particle with iron oxide [75, 76] . Synthetic HDL nanoparticles 40 and 41 ( Fig. 7) target atherosclerosis. In vivo imaging of genetically engineered hyperlipidemic (ApoE KO) mice with tail-vein injections of 3.25 and 4.36 mol/kg doses of 40 (relaxivity (T 1 ) of 10.4 mM -1 s -1 per particle, 1.5 T, 25 °C, and water at pH 7.4) demonstrated contrast enhancement of plaques (Fig. 8) [75] . In vivo imaging of ApoE KO mice with 41 (relaxivity (T 2 ) of 94.2 mM -1 s -1 , 1.41 T, and 40 °C) also demonstrated contrast enhancement of plaques using 30 mg (0.54 mmol) Fe/kg [76] .
Another iron-oxide-containing biomimetic used as a targeted agent is ferritin. Ferritin is a protein that stores iron and regulates levels of iron in the body. Consequently, endogenous ferritin can be used to recognize some ferritinrelated diseases using MRI [77] . Thus, ferritin provides a template to generate SPIO-based contrast agent mimics. Recombinant human H chain ferritin, 42, was used in vitro as a macrophage-targeted contrast agent, and these studies showed selective uptake of 42 by macrophages (incubated with 165 g (3 mol) Fe/mL of 42) resulting in contrast enhancement at 1.5 T [78] . In another study, cationic ferritin 43 was used as a basement-membrane-selective contrast agent to detect glomerulosclerosis [79] . Both ex vivo and in vivo imaging using 43 in rat models at 11.7 T detected disruptions of basement membranes; however, five intravenous injections of a relatively high dose (~5 mg (0.089 mmol) Fe/kg) was required to detect cationic ferritin accumulation in glomeruli in vivo: this high dose is a challenge for translation into clinical applications.
Recently, Yang and co-workers reported engineered proteins that chelate Gd III ions to produce stable high relaxivity contrast agents for MRI [86] . An example is a contrast agent containing an engineered cell adhesion protein 44 ( Fig. 7) with a domain to chelate Gd III ions. Agent 44 has a relaxivity of 117 mM -1 s -1 (1.5 T) enabling doses as low as 2.4 mol Gd III /kg for contrast-enhanced imaging. Using this approach, endogenous proteins can be mimicked to synthesize targeted contrast agents with higher efficiency.
While the structure-mimicking strategy enables the use of endogenous interactions to deliver agents, synthesizing targeted agents with the structure-mimicking strategy is challenging and not generalizable like the conjugation strategy. Therefore, the scope of targets and number of examples are limited relative to agents synthesized with the conjugation strategy. Some of these agents have high relaxivities and enhance contrast in vivo; however, more research is needed in this area to improve current mimetic agents and to find new biomimetics that form stable paramagnetic complexes and are specific for various tissues and diseases.
CONCLUSION
Targeted contrast agents enable the visualization of structural changes in organs or the expression of biological molecules, and these agents have the potential to aid in the diagnosis of diseases at early stages. In general, targeting ability is achieved by conjugating a targeting moiety to a contrast agent or by mimicking the structural features of targeting moieties with contrast agents. A large number of targeted agents have been synthesized with the conjugation strategy, and while conjugation of a single contrast-enhancing unit per targeting moiety enables selective imaging in the presence of high local concentrations of targets, many such contrast agents suffer from low sensitivity and require large doses to achieve contrast enhancement. The use of multiple contrastenhancing units in multimeric agents overcomes the limitation of sensitivity, but the large size of multimeric agents can cause difficulties with excretion. Synthesis of macromolecules smaller than the renal excretion threshold is a strategy to avoid this problem, but this strategy also influences relaxivity. Also, polydispersity of these systems can lead to difficulties with reproducibility. Relatively few examples of the mimicking strategy are reported for the design of targeted contrast agents because of the limited availability of biomimetics that form stable complexes with paramagnetic cations; however, recent advances in nanochemistry and biotechnology will likely lead to more opportunities for mimicking biologically important structures with contrast agents.
Except for one or two target-specific contrast agents that are clinically approved (MS-325) or in clinical-trials (texaphyrins), the majority of target-specific agents are in pre-clinical levels of research; however, successful in vivo imaging was reported with many pre-clinical studies, and these results shine positive light onto the future of the field. An area of where extra attention to detail will likely aid the field is the inclusion of as many experimental details as possible: the direct comparison of different studies is difficult because the conditions used for relaxivity measurements and imaging experiments are different (Table 1) , and improper comparisons could lead to misinterpretations of the efficiency of one agent compared to another. Finally, improvements to the selectivity, sensitivity, and biocompatibility of target-specific agents and the selection of new molecular targets using both the conjugation and mimicking strategies will likely enable translation into clinical applications for MRI. 
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